Summary of Conference Call Notes Company Overview - **Company**: 来凯医药 (LaiKai Pharmaceutical) - **Key Products**: LAE102 (ActRIIA), LAE002 (Afuresertib), LAE103 (ActRIIB), LAE123, LAE124 Industry Insights - **Market Focus**: The company is focused on the development of innovative therapies in the fields of muscle gain and fat loss, particularly through the ActRIIA and ActRIIB pathways. Key Points and Arguments LAE102 (ActRIIA) - **Clinical Data**: - In the Chinese MAD group, after 4 weeks, lean body mass increased by 4.6% and fat mass decreased by 3.6% - In the US SAD group, lean body mass increased by over 5% and fat mass decreased by over 2% - Safety profile is good with no racial differences observed [2][5][13] - **Future Plans**: - A 24-week MAD extension trial with 60 subjects has been initiated, with data expected in Q3 2026 - A phase II clinical trial in combination with GLP-1 is set to start soon [2][5][10] LAE002 (Afuresertib) - **Commercialization Timeline**: - Phase III trial completed enrollment in October 2025, with top-line data expected in Q2 2026 - NDA submission planned for late 2026, aiming for market launch in 2027 - Collaboration with Qilu Pharmaceutical for sales in Greater China, with a total agreement value of 2.045 billion RMB, including a pre-approval payment of 530 million RMB [2][12] - **Market Potential**: - Peak sales for similar drugs (e.g., AstraZeneca's Capivasertib) projected to reach 1-2 billion USD [12] Financial Performance - **2025 Financials**: - Revenue confirmed at 107 million RMB, primarily from LAD002 licensing agreement - Management and R&D expenses totaled 356 million RMB, focused on advancing ActRII pipeline - Loss narrowed from 254 million RMB in 2024 to 229 million RMB in 2025 - Cash reserves at 1.26 billion RMB, sufficient for 3-4 years of operations at a burn rate of approximately 350 million RMB per year [3][4][16] Competitive Landscape - **Differentiation**: - ActRII antibody is leading in the muscle gain and fat loss sector, outperforming preclinical small nucleic acid drugs - Unlike APOC3/AGT-targeting drugs that only reduce fat, ActRII also promotes muscle mass increase, providing a competitive edge [4][9] Pipeline Clarity - **Upcoming Milestones**: - LAE103 (ActRIIB) phase I trial initiated in Australia, with data expected in Q3 2026 - LAE123 (dual-targeting ActRIIA/B antibody) IND submission planned for 2026 - LAE124 (oral GIPR agonist) expected to complete PCC in 2026 [2][6][11] Strategic Partnerships - **BD Strategy**: - Open to collaborations with multinational pharmaceutical companies to accelerate overseas clinical development for LAE102 - Focus on partners with strong commitments and financial capabilities [13][15] R&D and Commercialization Capability - **Execution Strength**: - The company has demonstrated strong R&D capabilities and timely milestone achievements - Confidence in maintaining a leading position globally due to first-mover advantages and deep understanding of signaling pathways [16] Overall Outlook - **Future Expectations**: - Anticipation of significant milestones and catalysts in 2026 to enhance company valuation and investor returns [16]

Core Insights - The article highlights the significant breakthrough of LAE102, a drug developed by the company, in the competitive global metabolism and weight loss market, showcasing its potential to attract attention from both capital markets and clinical fields [4] Group 1: Drug Performance - LAE102 demonstrated remarkable results in a Phase I single-dose escalation study in the U.S., showing significant muscle gain and fat loss effects in healthy postmenopausal women after 4 weeks of treatment, with a 5.06% increase in lean body mass and a 0.12% decrease in fat mass compared to a placebo group [4] - Compared to competitors, LAE102 outperformed Bimagrumab in muscle gain within 4-5 weeks, while also showing strong fat loss effects, indicating its superior efficacy in the "muscle gain and fat loss" arena [5] Group 2: Safety and Development - The safety profile of LAE102 is impressive, with no serious adverse events reported, aligning closely with previous Phase I trial results in China, which enhances its potential as a leading drug in the muscle gain and fat loss sector [5] - The company is accelerating the development of LAE102 and actively engaging with potential partners to expedite global commercialization, positioning it as a highly sought-after project among major pharmaceutical companies in the future [6]

Core Insights - The article highlights the recognition of LaiKai Pharmaceutical (2105.HK) as a leading innovator in the biotech sector, winning the "Annual Investment Value Award" due to its robust R&D pipeline and strong growth potential [1][11] - The company is positioned to capitalize on the global shift towards true innovation in the pharmaceutical industry, particularly in the fields of metabolism and cancer treatment [1][11] Pipeline Breakthroughs and Commercialization - LaiKai Pharmaceutical has demonstrated differentiated competitive advantages in metabolism and cancer treatment, with a focus on the Activin-ActRII pathway [3] - The company's LAE102 monoclonal antibody for obesity has shown promising results in Phase I clinical trials, with a 4.6% increase in lean body mass and a 3.6% reduction in fat mass at a 6mg/kg dosage [3] - The FDA has approved the IND application for LAE103, targeting sarcopenic obesity and muscle-related diseases, while LAE123 is expected to enter clinical trials in 2026, enhancing the company's pipeline [3] Cancer Treatment Advancements - The AKT inhibitor LAE002 is in a critical stage of commercialization, with ongoing Phase III trials for HR+/HER2- breast cancer, expected to yield top-line data in mid-2026 [4] - The partnership with Qilu Pharmaceutical for LAE002's development and commercialization in China includes a potential total of 2.045 billion yuan in milestone payments, enhancing LaiKai's cash flow for future R&D [5] Policy and Capital Synergy - The Chinese innovative drug industry is experiencing a favorable development cycle, supported by policy, technology, and capital collaboration [7] - The average review time for innovative drug applications has been reduced to 225 working days, with a record 69 new drugs approved in 2025, facilitating faster market access [8] - The Chinese pharmaceutical industry is now the second largest globally, with a significant number of innovative drugs in development, indicating a growing recognition of Chinese innovation on the global stage [8] Conclusion - LaiKai Pharmaceutical is well-positioned to realize its value through its differentiated innovation, clear pipeline strategy, and efficient commercialization pathways, with the potential for sustainable returns for investors as products like LAE002 approach market approval [11]

Core Viewpoint - The company, Shiyao Group, has received FDA approval for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) to conduct clinical trials in the United States, with additional approval from China's National Medical Products Administration for trials starting in November 2025 [1] Group 1: Product Details - JMT206 specifically binds to both ActRIIA and ActRIIB receptors, blocking the interaction of activin A, myostatin, and growth differentiation factor 11 with ActRII, thereby inhibiting downstream signaling pathways [1] - The product aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in individuals who are obese or overweight and have at least one weight-related comorbidity [1] - The product is also designed to assist GLP-1 receptor agonists in achieving higher quality weight loss outcomes [1]

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) to conduct clinical trials in the United States, and it has also been approved by the National Medical Products Administration of China for clinical trials in China by November 2025 [1] Group 1: Product Details - JMT206 specifically binds to Activin receptor type IIA (ActRIIA) and IIB (ActRIIB), blocking the binding of Activin A, Myostatin (GDF8), and Growth Differentiation Factor 11 (GDF11) to Activin receptor type II (ActRII) [1] - The product aims to inhibit downstream signaling pathways, reduce muscle loss, and promote skeletal muscle maintenance and growth, achieving muscle gain and fat loss [1] - It also assists GLP-1 receptor agonists in achieving higher quality weight loss effects [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1] - Preclinical studies have shown that the product exhibits high bioavailability, good efficacy, and safety, indicating a high clinical development value [1]

Core Viewpoint - The approval of the monoclonal antibody drug JMT206 by the National Medical Products Administration of China marks a significant advancement for the company in the clinical trial phase, targeting weight management in obese or overweight individuals with related comorbidities [1] Group 1: Product Development - The drug JMT206 is a fully humanized recombinant monoclonal antibody that specifically binds to Activin receptor type IIA (ActRIIA) and IIB (ActRIIB), blocking the interaction of Activin A, Myostatin (GDF 8), and Growth Differentiation Factor 11 (GDF11) with Act RII [1] - The mechanism of action aims to inhibit downstream signaling pathways, thereby reducing muscle loss and promoting skeletal muscle maintenance and growth, achieving a muscle gain and fat loss effect [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated that JMT206 exhibits high bioavailability along with good efficacy and safety, indicating a high clinical development value [1] - The approved clinical indication focuses on weight management for obese or overweight individuals with at least one weight-related comorbidity [1]

Core Viewpoint - The announcement indicates that the drug JMT206, a fully humanized monoclonal antibody targeting Act RIIA/IIB, has received approval from the National Medical Products Administration of China to conduct clinical trials, highlighting its potential in obesity management and muscle preservation [1] Group 1: Product Details - JMT206 specifically binds to ActRIIA and ActRIIB, blocking the interaction of Activin A, GDF8, and GDF11 with Act RII, thereby inhibiting downstream signaling pathways [1] - The drug aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1] - It also assists GLP-1 receptor agonists in achieving higher quality weight loss outcomes [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in individuals who are obese or overweight with at least one weight-related comorbidity [1] - Preclinical studies have demonstrated high bioavailability, good efficacy, and safety, indicating significant clinical development value [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 臨床前研究顯示，該產品表現出較高的生物利用度以及良好的療效和安全性，具有較高的 臨床開發價值。 承董事會命 石藥集團有限公司 主席 蔡東晨 香港，2025年11月26日 – 1 – 重組全人源抗ACTRIIA / IIB單克隆抗體(JMT206) 在中國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的重組全人源抗Act RIIA / IIB單克隆抗體藥物(JMT206)（「該產品」）已獲中華 人民共和國國家藥品監督管理局批准，可在中國開展臨床試驗。 該產品可同時特異性結合激活素受體IIA型(ActRIIA)與 ...

Core Viewpoint - The article emphasizes the urgent need for a comprehensive approach to weight management in China, highlighting the alarming obesity rates and the associated health risks, while advocating for a shift from traditional weight loss methods to a holistic health ecosystem that integrates technology, policy, and individual responsibility [5][7][30]. Group 1: Obesity Crisis and Health Risks - By 2025, the overweight rate among Chinese adults is projected to reach 34.3%, with obesity rates at 16.4%, and a 12-fold increase in youth obesity over the past 15 years [5]. - If no effective measures are taken, by 2030, adult overweight and obesity rates could soar to 70.5%, with youth rates reaching 31.8% [5]. - Obesity is linked to over 200 diseases, leading to annual medical expenses exceeding 240 billion yuan, with chronic diseases like diabetes and cardiovascular issues on the rise [7]. Group 2: Comprehensive Health Ecosystem Development - The National Health Commission's "National Fitness Plan" promotes a dual focus on muscle gain and fat loss, moving away from the sole reliance on BMI for health assessments [8]. - Innovative products, such as a patented CLA + whey protein complex, have shown promising results in trials, with users averaging a muscle gain of 2.3 kg and fat loss of 4.7 kg over three months [9]. - The "smart fat-burning machine" initiative utilizes wearable devices to monitor metabolic health, with a specific formula enhancing basal metabolic rate by 12%-15% [10]. Group 3: New Frontiers in Weight Management - Community health initiatives in regions like Guangdong and Zhejiang are incorporating gut microbiome testing into routine health checks, offering personalized prebiotic prescriptions for obesity linked to microbiome imbalances [11]. - The integration of skin and fat management post-weight loss is emphasized, with guidelines recommending the inclusion of collagen and elastin in weight loss products [12]. - Advanced technologies, such as microencapsulated hyaluronic acid, are being developed to maintain skin elasticity during weight loss [13]. Group 4: Policy, Technology, and Community Engagement - The establishment of the "Metabolic Cloud Brain" platform aims to provide personalized recommendations for muscle gain, fat loss, and microbiome regulation through a simple scan [14]. - The "15-minute scientific weight loss circle" initiative in Beijing promotes community engagement by providing access to fitness resources and health monitoring [15]. Group 5: Avoiding Weight Loss Pitfalls - The weight loss market is plagued by misinformation, with 40% of products exaggerating their effectiveness, leading to consumer confusion and potential health risks [17]. - There is a significant gap in obesity treatment resources, with less than 15% of primary hospitals offering obesity management services, and a shortage of qualified weight loss surgeons [18]. Group 6: Future Outlook on Weight Management - The future of weight management is expected to leverage technologies like AR body fat scanning and AI-driven personalized plans, fostering a collaborative environment among government, businesses, and communities [22]. - The narrative of weight loss is shifting from mere calorie restriction to a more nuanced approach that balances muscle and fat management, gut health, and hormonal regulation [23].

Core Insights - The collaboration between LaiKai Pharmaceuticals and Qilu Pharmaceutical for the breast cancer candidate drug LAE002 is a significant deal valued at 2.045 billion RMB, with potential for additional sales royalties [1][4][5] - LAE002 is one of the leading AKT inhibitors in late-stage clinical development for breast and prostate cancer, indicating strong market potential and a promising partnership for commercialization [1][3][8] - The partnership exemplifies an optimal allocation of innovative and commercial resources, enhancing the prospects for both companies in the competitive oncology market [11] Financial Aspects - LaiKai Pharmaceuticals is set to receive a non-refundable upfront payment of up to 530 million RMB and milestone payments, with total potential earnings from the deal reaching 2.045 billion RMB [4][5] - The expected peak sales for LAE002 in China are projected to be around 2 billion RMB, with global peak sales potentially mirroring those of Capivasertib, which is estimated to reach 1-2 billion USD [9] Market Context - Breast cancer is a prevalent disease, with approximately 2.3 million new cases globally in 2022, making it a fertile ground for innovative therapies [6] - The HR+/HER2- subtype accounts for 60-70% of breast cancer cases, highlighting a significant unmet need for new treatment options, particularly for patients who develop resistance to existing therapies [6][8] Competitive Landscape - LAE002 is positioned as a strong competitor to other AKT inhibitors, demonstrating superior efficacy and safety profiles in clinical studies [8] - Qilu Pharmaceutical, recognized for its rapid market entry and strong performance in the pharmaceutical industry, is expected to leverage its capabilities to maximize the commercial potential of LAE002 [10][12] Strategic Implications - The partnership is indicative of a trend towards complementary resource matching between different types of pharmaceutical companies, which may lead to more effective drug development and commercialization strategies [11] - LaiKai's successful licensing of LAE002 not only validates its business development capabilities but also strengthens its financial position, allowing for further investment in its pipeline [12][13]